Don't Take a Position in Virios Therapeutics Stocks Without Knowing Its Fundamentals!

Virios Therapeutics logged a 75.9% change during today's afternoon session, and is now trading at a price of $1.1 per share.

Virios Therapeutics shares moved -83.6% over the last 52 weeks, with a high of $9.11 and a low of $0.22. During this time, the stock lagged the S&P 500 index by -83.0%. As of January 2022, the company's 50-day average price is $0.4. Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The small-cap Health Care company has 4 full time employees and is based in Alpharetta, GA. Virios Therapeutics has not offered any dividends in the last year.

The Company Has Irregular and Negative Cash Flows:

2019-12-31 2020-12-31 2021-12-31 2022-12-31
Revenue (k) $0 $0 $0 $0
Revenue Growth n/a n/a n/a n/a
Operating Margins n/a n/a n/a n/a
Operating Margins Growth n/a n/a n/a n/a
Net Margins n/a n/a n/a n/a
Net Margins Growth n/a n/a n/a n/a
Earnings Per Share -$0.51 -$2.1 -$1.92 -$1.1
EPS Growth n/a -311.76% 8.57% 42.71%
Diluted Shares (MM) 5 5 8 18
Free Cash Flow (k) -$2,092 -$3,895 -$15,690 -$11,468
FCF Growth n/a -86.18% -302.79% 26.91%

Virios Therapeutics has negative earnings for the current period, so its trailing twelve month P/E ratio is not meaningful. Its forward P/E isn't meaningful either because its guidance EPS is -0.42.

On the other hand, Virios Therapeutics is possibly undervalued in terms of its net assets because its P/B ratio is 2.8 compared to its sector average of 4.16.

Most of the Market Indicators on Virios Therapeutics Are Negative:

The company has an average amount of shares sold short since 2.2% of the company's shares are tied to short positions. Institutions own 10.7% of Virios Therapeutics's shares, while the insider ownership rate stands at 12.05%. The biggest shareholder is Renaissance Technologies, LLC with a 1% stake in the company worth approximately $258,940.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.